Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects

Rong Shi, Marek Honczarenko, Sean X. Zhang, +9

The Journal of Clinical Pharmacology

Healthy SubjectsImmunologyPharmacotherapyImmunotherapyPharmacokinetics +18

Fixed Dosing Versus Body Size—Based Dosing of Therapeutic Peptides and Proteins in Adults

Shuzhong Zhang, Rong Shi, Chunze Li, +2

The Journal of Clinical Pharmacology

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

Dan Lü, Tong Lu, Leonid Gibiansky, +11

CPT Pharmacometrics & Systems Pharmacology

ImmunologyUnconjugated MmaePharmacotherapyImmunotherapyPhysiologically-based Pharmacokinetic Modeling +17

Effects of 12-week supplementation of Citrus bergamia extracts-based formulation CitriCholess on cholesterol and body weight in older adults with dyslipidemia: a randomized, double-blind, placebo-controlled trial

Yong Cai, Guoqiang Xing, Shen Tian, +3

Lipids in Health and Disease

Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma

Tong Lu, Leonid Gibiansky, Xiaobin Li, +9

Leukemia & lymphoma/Leukemia and lymphoma

Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials

Divya Samineni, Hao Ding, Fang Ma, +9

The Journal of Clinical Pharmacology

Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699

Zheng Yang, Haiqing Wang, Theodora W. Salcedo, +11

Journal of Pharmacology and Experimental Therapeutics

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

Dan Lü, Tong Lu, Rong Shi, +11

Pharmaceutical Research

Lymphoid NeoplasiaOncologyPharmacokinetic ModelingMedicinePolatuzumab Vedotin +8

Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients

Verena Kirn, Rong Shi, Sabine Heublein, +9

Journal of Cancer Research and Clinical Oncology

MedicineGynecologyPathologyOncologyEpigenetics +3

Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE

Xianfeng Yu, Rong Shi, Xia Zhou, +4

Alzheimer s & Dementia